Low Troponin Concentrations May Reduce Hospital Admissions for Patients With Low-Risk MI
A strategy to identify patients with low-risk for myocardial infarction could benefit patients and healthcare providers
Acute Coronary Syndrome
Bioresorbable Scaffolds as Effective as Stents for Coronary Heart Disease
Although long-term follow-up is still required, bioresorbable scaffolds were comparably effective to drug-eluting metallic stents for coronary heart disease one year postsurgery.
New Technology Clears Acute Heart Failure Patients with a Low Risk of Adverse Events for Discharge
A study tests a decision tool that identifies emergency department patients with acute heart failure at a low risk for 30-day adverse events.
USPSTF Recommends Low-Dose Aspirin Regimen to Prevent Risk for Cardiovascular Disease
A recent USPSTF evidence review suggests that long-term, low-dose aspirin regimens can be used as a preventive measure in adults aged 50 to 69 years to combat cardiovascular disease.
Quit-Smoking Drug Not Associated with Heart Disease, Depression
The effective quit-smoking drug varenicline has been prescribed with FDA warnings of heart disease and depression, but recent research has found no evidence of elevated risk.
Quitting Smoking After Myocardial Infarction Improves Mental Health
Patients who quit smoking after an AMI may improve their long-term quality of life.
PRESERVATION I Trial Shows No Benefit for Bioabsorbable Cardiac Matrix Treatment in Patients With Myocardial Infarction
Researchers found no benefit in using Bioabsorbable Cardiac Matrix treatment in patients who sustained a heart attack when compared with a saline placebo.
Rapid, 1-Hour Troponin I Assay Successfully Diagnoses Acute Myocardial Infarction
Researchers have developed an algorithm for a rapid, 1-hour troponin I assessment to more quickly and accurately diagnose acute MIs in emergency department patients compared with the existing 3-hour assay.
No Benefit of Cyclosporine Demonstrated in Phase 3 CIRCUS Clinical Trial
In the phase 3 CIRCUS trial, the immunosuppressant drug cyclosporine held no benefits for patients who sustained ST-segment elevation myocardial infarctions.
- Loading...
Loading...
Next post in ESC Meeting Highlights
Loading... 
Loading...